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S U M M A R Y
Objective: To evaluate the performance of three interferon-gamma release assay (IGRA) kits in detecting
Mycobacterium tuberculosis infection in China.
Methods: A multicenter clinical trial was used to compare the effectiveness and application of the three
kits. A total of 1026 participants were enrolled at three hospitals, including 597 tuberculosis (TB)
patients diagnosed clinically (517 patients with pulmonary TB and 80 patients with extrapulmonary TB)
and 429 negative controls (244 patients with pulmonary disease but not TB, or with non-tuberculosis
mycobacterial lung diseases, and 185 healthy people). Detection performance indicators including
sensitivity, speciﬁcity, and the Youden index (YI) were used to evaluate performance.
Results: Through bacterial culture evaluation, 224 of the 517 pulmonary TB patients were positive and
all 429 negative controls were negative. When the gold standard bacterial methods were used, the
sensitivity, speciﬁcity, and YI were 89.7% (201/224), 91.1% (391/429), and 0.81 for T-SPOT.TB, 86.2%
(193/224), 87.2% (374/429), and 0.73 for QB-SPOT, and 83.9% (188/224), 88.6% (380/429), and 0.73 for
TB-IGRA, respectively. There were no signiﬁcant differences in the sensitivity and speciﬁcity of the three
kits.
Conclusions: The results showed that the three kits had very high sensitivity and speciﬁcity and
exhibited a good performance for the detection of M. tuberculosis infection.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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According to World Health Organization (WHO) reports,
tuberculosis (TB) remains a major global health problem, although
TB treatment has saved the lives of more than 22 million people. In* Corresponding authors. Fax: +86 10 58900779.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).2012, 8.6 million fell ill with TB and there were 1.3 million TB
deaths globally.1 The results of a Chinese national epidemiological
sampling investigation showed the infection rate of the population
infected with Mycobacterium tuberculosis to be 44.5% and the active
pulmonary TB (PTB) prevalence rate to be 367/100 000, and it was
estimated that there have been 4.51 million active PTB cases across
the country.2
In China, TB has generally been diagnosed by traditional
methods that rely on clinical symptoms together with the results
of bacteriology methods (including sputum smear microscopy and
bacterial culture), the tuberculin skin test (TST; puriﬁed proteinciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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However, the sensitivity of the sputum smear microscopy test is
very low, bacterial culture takes a long time to provide a diagnostic
end-point, the TST often displays serious false-positives and false-
negatives, and X-ray examination is non-speciﬁc, hence these
methods are not effective in diagnosing TB in a efﬁcient manner.4,5
The TB interferon-gamma release assay (IGRA) detects the
release of interferon-gamma (IFN-g) in fresh heparinized whole
blood samples from test subjects. In this assay, the blood samples are
incubated with mixtures of the two speciﬁc Mycobacterium antigens
present in M. tuberculosis: early secretory antigenic target 6 (ESAT-6)
and culture ﬁltrate protein 10 (CFP-10). All bacille Calmette–Gue´rin
(BCG) vaccine strains and most environmental mycobacteria are
devoid of ESAT-6 and CFP-10.6–9 Both the antigens elicit a strong
T-cell response in subjects with TB,10–14 and have been used for the
detection in both early and active TB and for subclinical infection.15,16
ESAT-6 and CFP-10 proteins are the focus of current research, and test
kits have also been commercialized in recent years.17–19 There are
two types of IGRA: the ﬁrst is an enzyme-linked immunospot
(ELISpot) assay that enumerates IFN-g-secreting T-cells, and the
other measures the IFN-g concentration in the supernatant of blood
by ELISA.20 This study was designed to compare the performance of
three commercial IGRA kits, including two domestic tests (TB.IGRA
and QB.SPOT) and one imported test (T-SPOT.TB), and to determine
whether these kits can be used reliably as the IGRA-based diagnostic
tools for the diagnosis of TB infection.
2. Materials and methods
This research was approved and permitted by the Ethics
Committee of the National Institute for Communicable Disease
Control and Prevention, Chinese Center for Disease Control and
Prevention, Beijing, China. All subjects provided signed informed
consent prior to study participation.
2.1. Clinical trial design and participants
This multicenter clinical trial employed a random blinded
method. Blood specimens, sputum samples, and clinical and
epidemiological information were collected for all suspected TB
patients visiting the pulmonary hospitals of Fujian, Hunan, and
Anhui provinces from September 1 to October 30, 2012. The
samples were tested and analyzed with bacteriological assays
(including sputum smear and bacterial culture) and the three
commercial cellular immune detection kits (TB.IGRA, QB.SPOT, and
T-SPOT.TB) simultaneously. The cases were segregated into three
groups based on the ‘pulmonary TB diagnosis standard’ of China,3
along with the results of the bacteriological tests and clinical
ﬁndings (clinical features and/or chest X-ray examination): (1) TB
group including PTB and extrapulmonary TB, (2) non-TB group,
comprising patients with pulmonary disease but not TB, or non-
tuberculosis mycobacterial lung diseases, and (3) the ‘healthy
group’. Samples that failed to give a clear result with the three kits
were excluded from the ﬁnal analysis.
The Chi-square test was used to compare the results of the three
tests. To evaluate the clinical efﬁcacy of the three kits, diagnostic
indices including the sensitivity, speciﬁcity, and Youden index (YI)
were adopted. All participants were negative for HIV/AIDS, as
diagnosed with the Chinese national diagnostic criteria for HIV/
AIDS.21 Participants with positive HIV results were excluded from
the trial. All sputum and blood samples were numbered and
processed by different skilled members of staff at different
laboratories, simultaneously. Thus, the tests were performed
double-blind in terms of sex, age, and clinical diagnosis of the
participants for the technicians conducting the experiments, as
well as the observers who collected the results at each hospital.2.2. Bacterial examination
Sputum samples from the PTB patients were subjected to smear
acid-fast staining, followed by Mycobacterium culture on Lo¨w-
enstein–Jensen medium.22 The end-point data obtained for both
sputum smear and bacterial culture using traditional bacteriologi-
cal methods were used to determine the bacterial diagnostic
results. If the sputum smear or bacterial culture result was positive,
then the sample was sputum smear or bacterial culture positive, if
not, it was negative. If the sputum smear and/or bacterial culture
results were positive, then the sample was bacteriologically
positive, if not, it was negative. Of the 517 PTB cases, 37 did not
provide sputum samples that were available for analysis.
2.3. The three commercial reagent kits
The clinical trial evaluated the clinical diagnostic effects of
three commercial IGRA reagent kits that have been authorized by
the China Food and Drug Administration (CFDA). These are
manufactured by Beijing Wantai Biopharm Co., Ltd, China, (TB-
IGRA), Beijing Kinghawk Pharmaceutical Co., Ltd, China (QB-SPOT),
and Oxford Immunotec, Oxford, UK (T-SPOT.TB). All of these tests
were conducted as per the manufacturers’ instructions and the
results identiﬁed as positive, negative, or indeterminate according
to recommended criteria.
2.4. In vitro release of IFN-g
The whole blood samples were collected by vein puncture
method followed by heparin anticoagulation and were incubated at
37 8C. Each sample was centrifuged to separate the whole blood,
which was then used for further analysis and measurements. This
was done either by enumerating the IFN-g-secreting T-cells (QB-
SPOT) or by measuring the IFN-g concentration (ELISA). For the
T-SPOT.TB kit, the peripheral blood mononuclear cell (PBMC) or
white blood cell components containing T-cells were separated from
the blood sample, washed, and counted. A pre-determined number
of PBMCs and antigens (ESAT-6 and CFP-10) speciﬁc to M.
tuberculosis infection were then added to the wells of a
microtiter plate coated with anti-IFN-g antibodies. The test is
based on the principle that the T-cells of an infected person
(active or dormant) will respond to the antigens and will secrete
IFN-g, which will be captured by anti-IFN-g antibodies coating
the ﬂoor of each well. The number of individual reacting T-cells
was enumerated through visualization (http://www.
Oxfordimmunotec.com). The testing process for the QB-SPOT
kit was performed as per the manufacturer’s instructions
(Beijing Kinghawk Pharmaceutical Co., Ltd, China). The TB-IGRA
uses a whole-blood test to measure the person’s immunity
towards M. tuberculosis. T-lymphocytes from most people
infected with M. tuberculosis will release IFN-g when mixed
with antigens (ESAT-6 and CFP-10). All the tests were performed
according to the manufacturer’s instructions (http://www.
Oxfordimmunotec.com, http://www.kinghawk828.com, http://
www.ystwt.cn).
2.5. Statistical analysis
The data were analyzed using IBM SPSS statistical software
package (version 19.0; IBM Corp., Armonk, NY, USA). Indetermi-
nate test results were excluded from the ﬁnal data analysis. The
Chi-square test was used to evaluate the difference between the
methods employed, and the difference was considered to be
signiﬁcant (p < 0.05) or non-signiﬁcant (p  0.05) by 95% conﬁ-
dence interval analysis. Agreement between results was quantiﬁed
using Cohen’s kappa statistic.23 According to the rules of Landis
Table 1
Distribution of serum samples from the three different hospitals in China (Fujian,
Hunan, and Anhui)
Sample, n (%) Total, n
TB Non-TB Healthy
Fujian Chest Hospital 179 (53.3) 101 (30.0) 56 (16.7) 336
Hunan Chest Hospital 281 (72.8) 47 (12.2) 58 (15.0) 386
Anhui Chest Hospital 137 (45.1) 96 (31.6) 71 (23.3) 304
Total 597 244 185 1026
TB, tuberculosis.
Table 2
Baseline data of the participants enrolled in the study
PTB (%) EPTB (%) Non-TB (%) Healthy (%) Total
Total 517 (50.4) 80 (7.8) 244 (23.8) 185 (18.0) 1026
Gender
Male 335 44 144 70 593
Female 167 31 99 112 409
Unknown 15 5 1 3 24
Age, years
Mean  SD 46.7  17.8 35.9  16.7 49.4  20.9 31.4  12.5
14 3 2 17 2 24
>14 507 76 224 177 984
PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis; SD, standard
deviation.
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k  0.4 indicates fair to good agreement, and k < 0.4 indicates
poor agreement.
3. Results
Of 1106 participants, 80 were excluded due to inconclusive
results for the three kits, thus 1026 participants were enrolled for the
evaluation: 517 PTB cases, 80 extrapulmonary TB cases, 244 non-TB
pulmonary disease patients, and 185 healthy people (Figure 1). The
non-TB pulmonary disease patients and the healthy people served as
negative controls. The number of participants from each hospital is
given in Table 1 (Fujian 336, Hunan 384, and Anhui 304). Baseline
information for the 1026 participants is provided in Table 2. For the
517 PTB cases, apart from those from whom a sputum sample could
not be collected and omitting the samples that were contaminated
during culturing, 224 bacteriological tests results were available for
comparison with the ‘gold standard’.
3.1. Comparison of the results (clinical diagnosis was used as the
reference method)
Among 597 clinically diagnosed TB patients, the sensitivity of T-
SPOT.TB, QB-SPOT, and TB-IGRA was 78.2%, 78.9%, and 74.9%,
respectively, with no signiﬁcant difference in sensitivity among the
three kits (p > 0.05). For the 80 extrapulmonary TB cases, the
sensitivity of T-SPOT.TB, QB-SPOT, and TB-IGRA was 66.3%, 70.0%,
and 68.8%, respectively, with no signiﬁcant difference in sensitivity
among the three kits (p > 0.05). For the 517 PTB patients, the
sensitivity of T-SPOT.TB, QB-SPOT, and TB-IGRA was 81.1%, 80.3%,
and 75.8%, respectively. This was compared to 24.7% (125/507) for
smear staining and 45.0% (219/487) for bacterial culture. There
was a signiﬁcant difference in sensitivity between the bacterial
methods and the three kits (p < 0.05). There was a signiﬁcant
difference in sensitivity of T-SPOT.TB and QB-SPOT between PTB
and extrapulmonary TB patients (p < 0.05), but not for TB-IGRA
(Tables 3–5).
3.2. Comparison of the results using bacteriological tests as the ‘gold
standard’
When the bacteriological test results were used as the ‘gold
standard’ to compare the results of the three kits, the sensitivity,T
1
597 TB  subject s 
517 Pulmonary TB 80  Ex trapulmonary T
Smear or  /b oth cultur e 
positive : 224 ; smear  an d 
culture ne gative:  25 6 
Posit ive: T-
SPOT.TB  414, QB -
SPOT 415, TB -
IGRA  39 2
Positive: T-
SPOT.TB 53, QB 
SPOT 56 , TB-IGR
55 
37 Results  
unknown
Figure 1. Flowchart of the speciﬁcity, and YI were 89.7%, 91.1%, and 0.81 for T-SPOT.TB, 86.2%,
87.2%, and 0.73 for QB-SPOT, and 83.9%, 88.6%, and 0.73 for TB-
IGRA, respectively. There was no signiﬁcant difference among the
three kits in sensitivity or speciﬁcity (p > 0.05). In total, 224 PTB
and 429 negative control cases (non-TB patients and healthy
people) when compared with the ‘gold standard’ gave YI and kappa
values of 0.81 and 0.80 (p < 0.01) for T-SPOT.TB, 0.73 and 0.72
(p < 0.05) for QB-SPOT, and 0.73 and 0.72 (p < 0.01) for TB-IGRA
(Table 5).
4. Discussion
The blood-based in vitro IGRA has been developed as a new
method for the detection of M. tuberculosis infection in recent
years. The novelty of IGRAs is based on the in vitro stimulation of
peripheral blood T-cells speciﬁc for the speciﬁc antigens ESAT-6hree hospit als
026 subjects 
429 Controls
The data  of  80  su bjects  we re excluded  as  the y did  
not have  clear  results  with  the  thre e kits 
All had  definite  results  fr om th e thr ee test s 
B 244 Healthy co ntrol s 185 Non-tuberc ulosis
-
A 
Positive:  
T-SPOT.TB 23 , QB-
SPOT 30, TB-IGRA 15 
Positive: T-
SPOT.TB 15, QB -
SPOT 25, TB-IGRA  
34 
clinical validation test.
Table 3
Positive detection rate of the three test kits
Methoda PTB EPTB Non-TB + healthy
people
T-SPOT.TB 80.1% (414/517) 66.3% (53/80) 8.9% (38/429)
QB-SPOT 80.3% (415/517) 70.0% (56/80) 12.8% (55/429)
TB-IGRA 75.8% (392/517) 68.8% (55/80) 11.4% (49/429)
PTB, pulmonary tuberculosis; EPTB, extrapulmonary tuberculosis.
a T-SPOT.TB: the enzyme-linked immunospot assay (Oxford Immunotec, Oxford,
UK). QB-SPOT: diagnostic kit for Mycobacterium tuberculosis stimulated T-cells
(immunospot method) (Beijing Kinghawk Pharmaceutical Co., Ltd). TB-IGRA:
diagnostic kit for T-cells infected with Mycobacterium tuberculosis (Beijing Wantai
Biopharm Co., Ltd).
Table 5
Comparison of results using the bacteriological test results as the ‘gold standard’ for
TB diagnosisa
T-SPOT.TB QB-SPOT TB-IGRA P-value
Sensitivity 89.7% (201/224) 86.2% (193/224) 83.9% (198/224) >0.05
Speciﬁcity 91.1% (391/429) 87.2% (374/429) 88.6% (380/429) >0.05
Youden index 0.81 0.73 0.73
Kappa value 0.80 0.72 0.72
TB, tuberculosis.
a Note: 224 were diagnosed positive and 429 were diagnosed negative with the
‘gold standard’.
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assessed by the induction of IFN-g. Earlier studies showed that the
IGRA has high sensitivity and speciﬁcity in diagnosing M.
tuberculosis infection.25
The purpose of this research was to evaluate the sensitivity
and speciﬁcity of three commercial IGRA kits in diagnosing M.
tuberculosis infection in China. The release of IFN-g from T-cells
in fresh heparinized whole blood samples was tested using
Chinese domestic kits (QB-SPOT and TB-IGRA) and an imported
kit (T-SPOT.TB), with simultaneous testing of the sputum
samples by conventional methods (sputum smear and M.
tuberculosis culture). Compared with conventional diagnostic
methods, the three commercial kits showed a very high
sensitivity (81.1%, 80.3%, and 75.8%) compared to smear staining
(24.7%) and bacterial culture (45.0%). It was found that 72.3%
(T-SPOT.TB), 75.8% (QB-SPOT), and 69.8% (TB-IGRA) of the
patients who were negative by smear staining and bacterial
culture, tested positive; thus these kits are also sensitive for
culture-negative or smear staining negative TB and extrapul-
monary TB samples. The study demonstrated that all three
commercial kits had very high accuracy in the detection of
M. tuberculosis infection and would be very good supporting
methods for the diagnosis of TB infection in primary medical
facilities or high burden areas in China.
A difference in sensitivity between PTB (T-SPOT.TB 80.1%, QB-
SPOT 80.3%) and extrapulmonary TB patients (T-SPOT.TB 66.3%,
QB-SPOT 70.0%) was found for both T-SPOT.TB and QB-SPOT, which
is in contrast to the results of previous studies,26–28 and this might
be due to the variation in sample size between PTB cases (n = 517)
and extrapulmonary TB cases (n = 80), or to some other reason that
was not identiﬁed in the trial.
Further research needs to be carried out, as there were no
agents available to test latent TB infection during the course of theTable 4
Detection results for pulmonary TB cases using bacteriology methods and the three ki
IGRA Smear staining Bacteria
Positive Negative Positive
T-SPOT.TB, n (%)
Positive 109 (87.2) 297 (77.7) 202 (92
Negative 16 (12.8) 85 (22.3) 17 (7.8
QB-SPOT, n (%)
Positive 106 (84.8) 301 (78.8) 192 (87
Negative 19 (15.2) 81 (21.2) 27 (12
TB-IGRA, n (%)
Positive 104 (83.2) 279 (73.0) 188 (85
Negative 21 (16.8) 103 (27.0) 31 (14
Total 125 382 219 
TB, tuberculosis; IGRA, interferon-gamma release assay.
a Note: Of 517 TB cases, 10 subjects showed no results for smear staining and 30 sustudy and there might have been some individuals with latent
infection in the negative control group; this would increase the
false-positive rate and thus lead to a low speciﬁcity in the negative
control group. Thus results need to be assessed in combination
with clinical symptoms and the results of traditional diagnostic
methods (culture and smear staining), and with contact history,
for positive results in healthy individuals and to improve
diagnosis.
This study had a good sample representation as it was based on
observations in referral TB hospitals and the subjects came from
different regions in these provinces of China. A performance
evaluation was carried out by comparing IGRA results with
bacterial methods to avoid the inﬂuence of misdiagnosis of active
TB. However, the bacterial tests could not be performed for the
extrapulmonary TB group as sputum samples or other types of
specimen were not available. Thus, we could not make compar-
isons with the ‘gold standard method’ for extrapulmonary TB
detection. This was a limitation of the present study and needs
further research.
In a study on cytokine gene expression in the M. tuberculosis-
infected guinea pig model, the expression of IFN-g was induced at
between 3 and 6 weeks of infection and gradually decreased.29
Such an effect might have inﬂuenced the accuracy of test
performance, as the duration of infection in the participants
enrolled in this study was unclear.
In conclusion, the data obtained in the current study suggest
that the three commercial kits have comparable detection
performance in PTB when the bacteriological method is used as
the ‘gold standard’. These will also be a very useful aid in the
clinical detection and diagnosis of M. tuberculosis infection,
especially in patients with smear-negative and culture-nega-
tive and extrapulmonary TB. This will be beneﬁcial for TB
control in China.tsa
l culture Total smear + culture
 Negative Positive Negative
.2) 189 (70.5) 201 (89.7) 185 (72.3)
) 79 (29.5) 23 (10.3) 71 (27.7)
.7) 200 (74.6) 193 (86.2) 194 (75.8)
.3) 68 (25.4) 31 (13.8) 62 (24.2)
.8) 184 (68.7) 188 (83.9) 178 (69.5)
.2) 84 (31.3) 36 (16.1) 78 (30.5)
268 224 256
bjects showed no results for bacterial culture.
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